scholarly journals Young patient with treatment-resistant schizophrenia drastically improved by combination of clozapine and maintenance electroconvulsive therapy: a case report

2019 ◽  
Vol Volume 12 ◽  
pp. 185-188 ◽  
Author(s):  
Masashi Ito ◽  
Yasuto Kunii ◽  
Sho Horikoshi ◽  
Itaru Miura ◽  
Shuntaro Itagaki ◽  
...  
Keyword(s):  
Case Report ◽  
Young Patient ◽  
Electroconvulsive Therapy ◽  
Treatment Resistant

Brain-derived neurotrophic factor and electroconvulsive therapy in a schizoaffective patient with treatment-resistant paranoid-hallucinatory symptoms

2011 ◽  
Vol 26 (S2) ◽  
pp. 1148-1148
Author(s):  
G. Martinotti ◽  
V. Ricci ◽  
M. Di Nicola ◽  
C. Caltagirone ◽  
P. Bria ◽  
...  
Keyword(s):  
Case Report ◽  
Electroconvulsive Therapy ◽  
Neurotrophic Factor ◽  
Poor Response ◽  
Serum Levels ◽  
Brain Derived Neurotrophic Factor ◽  
Treatment Resistant ◽  
Schizophrenic Patients ◽  
General Improvement ◽  
The Relationship

It has been proposed that deficits in the production and the utilization of brain-derived neurotrophic factor (BDNF) may contribute to the pathogenesis of schizophrenia. At the same time, electroconvulsive therapy (ECT) has been shown to induce a robust increase of BDNF protein in animal models. These findings suggest that one putative mechanism of action of ECT is the regulation of BDNF and/or related neurotrophins. In this case report a 54-year-old man with severe treatment-resistant schizophrenic symptoms was treated with ECT. In order to evaluate the effect of ECT on BDNF serum levels, we collected a blood sample before each ECT session. During the course of ECT treatment the paranoid and hallucinatory symptoms gradually improved while BDNF levels increased over time. In addition, there was a general improvement of its positive and negative schizophrenic symptoms and depressive state.In conclusion, this case report further validates the therapeutic efficacy of ECT in schizophrenic patients with inadequate or poor response to traditional treatments. Moreover, ECT therapeutic effect is associated with an increase in BDNF serum levels. Further studies are needed to characterize the relationship between BDNF and ECT in patients with schizophrenia symptoms.

scholarly journals Worsening of movement disorder following treatment with electroconvulsive therapy in a patient with Huntington’s disease

2019 ◽  
Vol 12 (8) ◽  
pp. e230389 ◽  
Author(s):  
Hesitha Abeysundera ◽  
Allan Campbell ◽  
Shanthi Sarma
Keyword(s):  
Case Report ◽  
Huntington's Disease ◽  
Movement Disorder ◽  
Huntington’S Disease ◽  
Electroconvulsive Therapy ◽  
Movement Disorders ◽  
Treatment Resistant Depression ◽  
Treatment Resistant ◽  
Medical Practitioners ◽  
Resistant Depression

This paper describes a patient who presented with treatment-resistant depression with comorbid anxiety symptoms in the context of Huntington’s disease (HD) and developed worsening movement disorder symptoms after commencing electroconvulsive therapy (ECT) for depression. The aim of this case report is to provide medical practitioners with a greater awareness of the possibility of worsening movement disorders when using ECT for depression in a patient with HD.

scholarly journals Repetitive transcranial magnetic stimulation induced hypomanic symptoms in a woman with a history of electroconvulsive therapy induced mania:  a case report

F1000Research ◽  
2013 ◽  
Vol 2 ◽  
pp. 284 ◽  
Author(s):  
Noah S. Philip ◽  
S. Louisa Carpenter
Keyword(s):  
Major Depressive Disorder ◽  
Case Report ◽  
Transcranial Magnetic Stimulation ◽  
Electroconvulsive Therapy ◽  
Magnetic Stimulation ◽  
Repetitive Transcranial Magnetic Stimulation ◽  
Treatment Resistant ◽  
Major Depressive ◽  
Psychiatric Illnesses ◽  
History Of

Repetitive transcranial magnetic stimulation (rTMS) is a comparatively novel option for the treatment of major depressive disorder (MDD) and other psychiatric illnesses. Previous research has shown rTMS to be safe and without significant side effects compared to pharmacologic options. However, rare cases of rTMS-induced mania have been reported. This case report describes such an affective switch in a 52 year old female veteran with treatment-resistant MDD and a history of electroconvulsive therapy (ECT)-induced mania. Six treatments of rTMS were administered at 5 Hz for a total of 3000 pulses per day, when the patient began to display multiple hypomanic symptoms. These symptoms decreased after the termination of treatment and abated within a couple of days. In conclusion, caution should be used when administering rTMS to patients with a history of ECT-induced mania.

scholarly journals Saving the Fetus in Maternal Schizophrenia: The Role and Safety of Electroconvulsive Therapy (ECT) in Pregnancy.

2018 ◽  
Vol 1 (1) ◽  
pp. 48-52
Author(s):  
Othman Abdul Karim ◽  
Noraslawati R ◽  
Anisah J ◽  
Syaratul Emma H
Keyword(s):  
Case Report ◽  
Side Effects ◽  
Electroconvulsive Therapy ◽  
First Trimester ◽  
Treatment Resistant ◽  
Pharmacological Interventions ◽  
Antipsychotic Medications ◽  
Long Duration ◽  
Clinical Dilemma ◽  
In Pregnancy

Introduction: Managing schizophrenia during pregnancy often presents a clinical dilemma. Although pharmacological interventions are mostly effective for these disorders during pregnancy, there are few drawbacks for this approach. The potential teratogenicity and long duration of interventions required to control the symptoms somehow limits its usage during pregnancy.Here we described a case report of treatment-resistant schizophrenia successfully treated with ECT without obvious complication to the mother and her baby.Conclusion: Electroconvulsive therapy is an ideal alternative treatment for a patient with schizophrenia during pregnancy. ECT also will eliminate the potential side effects of antipsychotic medications on the mother and teratogenicity effect to the fetus, especially during the first trimester.

scholarly journals Gamma-hydroxybutyric acid-induced organic delirium complicated by polydrug use successfully treated with electroconvulsive therapy: a case report

2021 ◽  
Vol 15 (1) ◽  
Author(s):  
Mads F. Kjærgaard ◽  
Poul Videbech ◽  
Jens J. Nørbæk ◽  
Bjørn H. Ebdrup
Keyword(s):  
Case Report ◽  
Electroconvulsive Therapy ◽  
Psychiatric Ward ◽  
High Dose ◽  
Line Treatment ◽  
Hydroxybutyric Acid ◽  
Treatment Resistant ◽  
First Line ◽  
Polydrug Use ◽  
First Line Treatment

Abstract Background Patients with gamma-hydroxybutyric acid withdrawal symptoms are at high risk of developing organic delirium, which can be fatal. The recommended first-line treatment is benzodiazepines, but treatment-resistant cases are frequent. Here we describe a case of successful bilateral electroconvulsive therapy in a patient with severe and highly agitated acute organic delirium induced by gamma-hydroxybutyric acid withdrawal and complicated by polydrug use resistant to first-line treatment. To our knowledge, this is the first report on the effect of electroconvulsive therapy on treatment-resistant delirium caused by gamma-hydroxybutyric acid withdrawal. Case presentation A 21-year-old Danish man diagnosed with untreated attention deficit hyperactivity disorder developed severely agitated acute organic delirium caused by gamma-hydroxybutyric acid withdrawal in a Danish psychiatric ward. The patient was subjected to physical restraints and transferred to the intensive care unit for treatment. During the next 10 days, the patient showed no clinical improvement despite first-line, high-dose benzodiazepines along with intense supportive treatment with propofol, phenobarbital, and antipsychotics. On day 11, bilateral frontotemporal electroconvulsive therapy treatment was initiated and full clinical recovery was obtained after four sessions. Discussion The full clinical remission after four electroconvulsive therapy sessions, strongly supports that electroconvulsive therapy may be an effective treatment when severe delirium induced by gamma-hydroxybutyric acid withdrawal is resistant to conventional first-line treatment with benzodiazepines. Moreover, this case illustrates that clinically effective seizures were achieved despite intensive concurrent exposure to anticonvulsive drugs. Therefore, this case report encourages consideration of electroconvulsive therapy in patients with gamma-hydroxybutyric acid delirium who are resistant to psychopharmacological treatment.

scholarly journals Propofol-Remifentanil Combination for Management of Electroconvulsive Therapy in a Patient with Neuroleptic Malignant Syndrome

2012 ◽  
Vol 2012 ◽  
pp. 1-3
Author(s):  
Modabber Arasteh ◽  
Shoaleh Shami ◽  
Karim Nasseri
Keyword(s):  
Case Report ◽  
Neuroleptic Malignant Syndrome ◽  
Male Patient ◽  
Electroconvulsive Therapy ◽  
Muscle Relaxant ◽  
Treatment Resistant ◽  
Successful Management ◽  
Therapy Sessions

Electroconvulsive therapy can be effective in severe or treatment resistant neuroleptic malignant syndrome patients. Anesthesia and use of muscle relaxant agents for electroconvulsive therapy in such patients may encounter anesthesiologists with specific challenges. This case report describes successful management of anesthesia in 28-year-old male patient undergoing eight electroconvulsive therapy sessions for treatment of neuroleptic malignant syndrome.

Sign in / Sign up

Export Citation Format

Share Document